Matt Pappas1,2,3, Sanjay Jolly4, Sandeep Vijan5,6. 1. VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, 2800 Plymouth Rd., NCRC Bldg. 16, Ann Arbor, MI, 48105, USA. pappasm@umich.edu. 2. Department of Internal Medicine, Division of General Internal Medicine, The University of Michigan Health System, Ann Arbor, MI, USA. pappasm@umich.edu. 3. The University of Michigan, Ann Arbor, MI, USA. pappasm@umich.edu. 4. The University of Michigan, Ann Arbor, MI, USA. 5. VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, 2800 Plymouth Rd., NCRC Bldg. 16, Ann Arbor, MI, 48105, USA. 6. Department of Internal Medicine, Division of General Internal Medicine, The University of Michigan Health System, Ann Arbor, MI, USA.
Abstract
BACKGROUND: Proton-pump inhibitors (PPIs) are commonly used among medical inpatients, both for prophylaxis against upper gastrointestinal bleeding (UGIB) and continuation of outpatient use. While PPIs reduce the risk of UGIB, they also appear to increase the risk of hospital-acquired pneumonia (HAP) and Clostridium difficile infection (CDI). Depending upon the underlying risks of these conditions and the changes in those risks with PPIs, use of proton-pump inhibitors may lead to a net benefit or net harm among medical inpatients. OBJECTIVE: We aimed to determine the net impact of PPIs on hospital mortality among medical inpatients. DESIGN: A microsimulation model, using literature-derived estimates of the risks of UGIB, HAP, and CDI among medical inpatients, along with the changes in risk associated with PPI use for each of these outcomes. The primary outcome was change in inpatient mortality. PARTICIPANTS: Simulated general medical inpatients outside the intensive care unit (ICU). MAIN MEASURE: Change in overall mortality during hospitalization. KEY RESULTS: New initiation of PPI therapy led to an increase in hospital mortality in about 90% of simulated patients. Continuation of outpatient PPI therapy on admission led to net increase in hospital mortality in 79% of simulated patients. Results were robust to both one-way and multivariate sensitivity analyses, with net harm occurring in at least two-thirds of patients in all scenarios. CONCLUSIONS: For the majority of medical inpatients outside the ICU, use of PPIs likely leads to a net increase in hospital mortality. Even in patients at particularly high risk of UGIB, only those at the very lowest risk of HCAP and CDI should be considered for prophylactic PPI use. Continuation of outpatient PPIs may also increase expected hospital mortality. Apart from patients with active UGIB, use of PPIs in hospitalized patients should be discouraged.
BACKGROUND: Proton-pump inhibitors (PPIs) are commonly used among medical inpatients, both for prophylaxis against upper gastrointestinal bleeding (UGIB) and continuation of outpatient use. While PPIs reduce the risk of UGIB, they also appear to increase the risk of hospital-acquired pneumonia (HAP) and Clostridium difficile infection (CDI). Depending upon the underlying risks of these conditions and the changes in those risks with PPIs, use of proton-pump inhibitors may lead to a net benefit or net harm among medical inpatients. OBJECTIVE: We aimed to determine the net impact of PPIs on hospital mortality among medical inpatients. DESIGN: A microsimulation model, using literature-derived estimates of the risks of UGIB, HAP, and CDI among medical inpatients, along with the changes in risk associated with PPI use for each of these outcomes. The primary outcome was change in inpatient mortality. PARTICIPANTS: Simulated general medical inpatients outside the intensive care unit (ICU). MAIN MEASURE: Change in overall mortality during hospitalization. KEY RESULTS: New initiation of PPI therapy led to an increase in hospital mortality in about 90% of simulated patients. Continuation of outpatient PPI therapy on admission led to net increase in hospital mortality in 79% of simulated patients. Results were robust to both one-way and multivariate sensitivity analyses, with net harm occurring in at least two-thirds of patients in all scenarios. CONCLUSIONS: For the majority of medical inpatients outside the ICU, use of PPIs likely leads to a net increase in hospital mortality. Even in patients at particularly high risk of UGIB, only those at the very lowest risk of HCAP and CDI should be considered for prophylactic PPI use. Continuation of outpatient PPIs may also increase expected hospital mortality. Apart from patients with active UGIB, use of PPIs in hospitalized patients should be discouraged.
Entities:
Keywords:
hospital medicine; medical decision making; modeling; simulation
Authors: Michael D Howell; Victor Novack; Philip Grgurich; Diane Soulliard; Lena Novack; Michael Pencina; Daniel Talmor Journal: Arch Intern Med Date: 2010-05-10
Authors: Erik R Dubberke; Anne M Butler; Kimberly A Reske; Denis Agniel; Margaret A Olsen; Gina D'Angelo; L Clifford McDonald; Victoria J Fraser Journal: Emerg Infect Dis Date: 2008-07 Impact factor: 6.883
Authors: Claudia C Orelio; Pauline Heus; Judith J Kroese-van Dieren; René Spijker; Barbara C van Munster; Lotty Hooft Journal: J Gen Intern Med Date: 2021-02-02 Impact factor: 5.128
Authors: Anca Trifan; Carol Stanciu; Irina Girleanu; Oana Cristina Stoica; Ana Maria Singeap; Roxana Maxim; Stefan Andrei Chiriac; Alin Ciobica; Lucian Boiculese Journal: World J Gastroenterol Date: 2017-09-21 Impact factor: 5.742
Authors: Travis J Kochan; Michelle S Shoshiev; Jessica L Hastie; Madeline J Somers; Yael M Plotnick; Daniela F Gutierrez-Munoz; Elissa D Foss; Alyxandria M Schubert; Ashley D Smith; Sally K Zimmerman; Paul E Carlson; Philip C Hanna Journal: mSphere Date: 2018-09-05 Impact factor: 4.389